Examples of treatment of lung cancer with axitinib/axitinib

Axitinib/Axitinib is a tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor (VEGFR), which has attracted widespread attention in the treatment of non-small cell lung cancer (NSCLC) in recent years. Because lung cancer patients are often diagnosed at an advanced stage, it is crucial to explore effective treatments. Axitinib provides a new possible treatment option for patients with non-small cell lung cancer by inhibiting tumor angiogenesis.

In clinical studies, axitinib has shown a strong inhibitory effect onVEGFR, which can improve the tumor microenvironment and thereby prevent tumor growth and metastasis. In an experiment involving mice carrying the human non-small cell lung cancer A549 cell line, the researchers combined axitinib with radiation therapy to evaluate its efficacy against lung tumors. Through quantitative assessment of lung tumor nodules, the results showed that axitinib combined with radiotherapy can significantly reduce tumor volume, and the combination treatment performed well in terms of safety, with no obvious heart, liver, or kidney damage observed.

At the same time, under long-term axitinib treatment, the weight loss of mice was also controlled to a minimum, showing the advantages of this drug in side effect management. These results provide a certain theoretical basis for the potential application of axitinib in non-small cell lung cancer. However, although axitinib improved progression-free survival (PFS) in some studies, clinical data to date have not fully demonstrated its improvement in overall survival (OS). Therefore, the specific role of axitinib in the treatment of non-small cell lung cancer still needs further clinical trials to verify.

Reference materials:https://pubmed.ncbi.nlm.nih.gov/23452008/